Redefining the value in partnerships ahead of DCAT Week

As the industry emerges from a prolonged funding slowdown, the roundtable highlights cautious optimism. Rather than a broad-based recovery, participants describe a selective, research-driven uptick focused on clinic-ready assets and higher-complexity modalities. Discussions have shifted from speculative experimentation to practical considerations, including manufacturability, timeline efficiency and the ability to scale reliably. This suggests growth that is deliberate, technology selective and weighted toward assets with clearer commercial pathways.

LATEST VIDEO

Latest news

11th June 2026

Johnson & Johnson Expands Oncology Pipeline with $1 Billion Firefly Bio Acquisition

10th June 2026

Axplora consolidates UDCA manufacturing at Vizag site to strengthen integrated global supply and support future growth

10th June 2026

Symeres expands spray drying capabilities to accelerate complex small molecule development

9th June 2026

AmMax Bio Licenses Antibody-Drug Conjugate Technology for Hematological Cancers from Lonza

9th June 2026

Lonza Appoints Hans Trees as Global Head of Communications

9th June 2026

GSK to Acquire Nuvalent in $10.6 Billion Deal

5th June 2026

BIO Unveils Dynamic Main Stage Lineup for 2026 Convention, Highlighting Innovation and Impact

4th June 2026

Stipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies

3rd June 2026

Lonza Advances Integrated DNA to IND Programs Through Acceleration, De Risking, and Innovation

3rd June 2026

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care

2nd June 2026

CPHI Americas relocates to Miami for 2027 to support global connectivity as part of the event’s evolution

This week’s featured articles

A woman’s view from the HAS Group

Breaking Barriers: Women Scientists Rising to Leadership in Pharma

Strategic Growth in Biologics Manufacturing: Insights from Lonza's Acquisition of the Vacaville Site

Grifols’ supply chain strategy offers lessons beyond saline

Axplora: Mastering complexity

Partnered with top industry events and organisations